ALEXANDER MARGARET A. 4
4 · Ovid Therapeutics Inc. · Filed Mar 2, 2026
Research Summary
AI-generated summary of this filing
Ovid (OVID) CEO Margaret Alexander Sells Shares, Receives Award
What Happened
Margaret A. Alexander, President & CEO and a director of Ovid Therapeutics (OVID), had two transactions reported. On 2026-02-23 she disposed of 11,656 shares in a sell-to-cover transaction for approximately $16,901 (weighted avg ~$1.45). On 2026-02-26 she was granted/acquired a derivative award covering 1,435,000 shares at $0.00 (no cash paid at grant).
Key Details
- Sale: 11,656 shares sold on 2026-02-23; weighted average price reported $1.45 (sales ranged $1.45–$1.48); total proceeds ~$16,901. Footnote: this was a mandatory "sell to cover" to satisfy tax withholding (not a discretionary sale).
- Award/Derivative: 1,435,000 shares reported as acquired on 2026-02-26 at $0.00 (derivative/option grant).
- Vesting: The award/option vests in 48 equal monthly installments beginning March 20, 2026, subject to continued service.
- Shares owned after transaction: Not specified in the provided excerpt—see the full Form 4 for final ownership totals.
- Filing timeliness: Transaction date 2/23/2026; Form 4 filed 3/02/2026 — this filing was submitted after the typical 2‑business‑day window (i.e., filed late).
Context
- The small sale was a routine sell-to-cover for tax withholding tied to vesting; it should not be read as a discretionary bearish signal.
- The large 1.435M‑share entry is a derivative grant (likely a stock option or restricted award) that vests monthly, meaning the economic benefit is realized over time and is contingent on continued service.
Insider Transaction Report
Form 4
ALEXANDER MARGARET A.
DirectorPresident and CEO
Transactions
- Sale
Common Stock
[F1][F2]2026-02-23$1.45/sh−11,656$16,901→ 61,750 total - Award
Employee Stock Option (Right to Buy)
[F3]2026-02-26+1,435,000→ 1,435,000 totalExercise: $1.65Exp: 2036-02-25→ Common Stock (1,435,000 underlying)
Footnotes (3)
- [F1]Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
- [F2]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.45 to $1.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2026, subject to the Reporting Person's continued services through each such date.
Signature
/s/ Jeffrey Rona, Attorney-in-Fact|2026-03-02